我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 Insmed, Inc.
相关临床试验
0
0 进行中
药物批准
3
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
EMA
European Medicines Agency
- The UK MHRA has granted marketing authorization for brensocatib (Brinsupri), marking the first medicine specifically licensed to treat non-cystic fibrosis bronchiectasis in the UK. - The treatment targets dipeptidyl peptidase 1 protein to prevent lung inflammation and flare-ups in patients aged 12 and older who have experienced two or more symptom exacerbations in the past year. - Brensocatib is administered as a once-daily oral tablet, with common side effects including respiratory infections, gastrointestinal issues, and skin-related reactions.
